Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» antibody-drug conjugate
antibody-drug conjugate
Merck develops new technology to address solubility and speed to market challenges of ADCs
Biopharma Reporter
Thu, 10/28/21 - 10:55 am
Merck
drug manufacturing
antibody-drug conjugate
ESMO: Daiichi unveils first early peek at next-gen ADC as analysts see strong data against rivals
Fierce Biotech
Fri, 09/17/21 - 11:06 am
ESMO
Daiichi Sankyo
antibody-drug conjugate
DS-7300
Seagen veteran-led ProfoundBio gets $55M to bring cancer drugs to the clinic
MedCity News
Mon, 07/12/21 - 11:32 pm
ProfoundBio
cancer
antibody-drug conjugate
funding
Seagen
Bristol Myers pays $650M for rights to Eisai's phase 1 ADC
Fierce Biotech
Fri, 06/18/21 - 10:11 am
Bristol Myers Squibb
antibody-drug conjugate
MORAb-202
Eisai
Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test
Endpoints
Tue, 06/8/21 - 11:21 am
clinical trials
antibody-drug conjugate
breast cancer
Byondis
ADC developer, Iksuda Therapeutics, closes $47m financing round
Biopharma Reporter
Mon, 06/7/21 - 08:26 pm
Iksuda
funding
antibody-drug conjugate
New JV from upstart biotechs Pyxis, Alloy aims for rapid drug development in cancer, autoimmune diseases
Fierce Biotech
Tue, 05/25/21 - 11:12 am
Pyxis Oncology
Alloy Therapeutics
Kyma Therapeutics
cancer
autoimmune disease
antibody-drug conjugate
AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it's adding more heat under Gilead's Trodelvy
Endpoints
Sun, 05/9/21 - 10:58 pm
AstraZeneca
Daiichi Sankyo
TNBC
antibody-drug conjugate
AstraZeneca drops BCMA drug after seeing early clinical data
Fierce Biotech
Fri, 04/30/21 - 10:35 am
AstraZeneca
antibody-drug conjugate
MEDI2228
Multiple Myeloma
Adcendo raises €51M series A round to pursue 'ideal' ADC target
Fierce Biotech
Thu, 04/29/21 - 10:48 am
Adcendo
antibody-drug conjugate
funding
ADC Therapeutics gets the nod from the FDA for its CD19-targeted antibody drug conjugate
Biopharma Reporter
Mon, 04/26/21 - 11:55 am
ADC Therapeutics
Zynlonta
antibody-drug conjugate
FDA
relapsed or refractory diffuse large B-cell lymphoma
Macrogenics takes another shot at a novel immune checkpoint
EP Vantage
Fri, 04/23/21 - 11:16 am
Macrogenics
MGC018
antibody-drug conjugate
After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B
Fierce Biotech
Tue, 03/30/21 - 11:49 am
Pyxis
Pfizer
funding
venture capital
antibody-drug conjugate
WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer
Endpoints
Fri, 01/29/21 - 10:03 am
AstraZeneca
WCLC
antibody-drug conjugate
datopotomab deruxtecan
Mersana starts to lose its shine
EP Vantage
Wed, 01/6/21 - 10:38 am
Mersana
ovarian cancer
XMT-1536
antibody-drug conjugate
New antibody-drug conjugate partnership has oncology focus
Biopharma Reporter
Wed, 12/16/20 - 10:32 pm
Sterling Pharma Solutions
CDMOs
oncology
cancer
antibody-drug conjugate
Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race
Fierce Biotech
Thu, 12/10/20 - 11:27 am
Boehringer Ingelheim
NBE Therapeutics
M&A
Merck
antibody-drug conjugate
ROR1
Lonza plots 2 manufacturing suites for antibody-drug conjugates at Switzerland site
Fierce Pharma
Wed, 12/2/20 - 11:49 pm
Lonza
drug manufacturing
antibody-drug conjugate
Genmab axes an ADC development program after the data fail to impress
Endpoints
Tue, 11/24/20 - 11:18 pm
Genmab
antibody-drug conjugate
enapotamab vedotin
ADC gets priority review for anti-CD19 blood cancer drug
Fierce Biotech
Fri, 11/20/20 - 11:12 am
FDA
ADC Therapeutics
antibody-drug conjugate
Lonca
relapsed or refractory diffuse large B-cell lymphoma
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
next ›
last »